Gaillimh, Ireland
Gaillimh, Ireland

The National University of Ireland, Galway is a constituent university of the National University of Ireland. It is a tertiary-level educational institution located in Galway, Ireland. The university was founded in 1845 as Queen's College, Galway and was more recently known as University College, Galway . Wikipedia.

SEARCH FILTERS
Time filter
Source Type

Patent
National University of Ireland | Date: 2017-07-26

The invention is concerned with a pharmaceutical and industrial iodophor preparation, its synthesis and potential applications. The compound has predictable antimicrobial activities. Furthermore, this iodophor is much more stable in the presence of organic material than traditional iodophors. The compositions release free iodine when in solution, which provides the antimicrobial activity.


Patent
National University of Ireland | Date: 2017-08-09

A device suitable for use in a body lumen and comprises an elongated control member having a distal and a proximal end, and a radially expansible member disposed at or near the distal end and adapted for collection and/or shearing of matter (i.e. thrombus) from a wall of the body lumen (i.e. a vein or an artery). The radially expansible member has a proximal end and a distal end and is adjustable between a contracted orientation and an expanded orientation. The elongated control member comprising a proximal arm connected at or adjacent to the proximal end of the radially expansible member and a distal arm connected at or adjacent to the distal end of the radially expansible member such that movement of one arm relative to the other arm effects adjustment of the diameter or radial strength of the radially expansible member. The device comprises a control mechanism operatively connected to both arms and adapted to provide resistance to the movement of one arm relative to the other. The control mechanism may be a biasing means, a brake means, or both.


Patent
National University of Ireland | Date: 2015-08-06

The invention relates to branched polymers which find use in gene therapy applications as nucleic acid transfection agents. In particular, the invention provides biodegradable, hyperbranched polymers which can be used in gene delivery and which provide improved transfection efficiencies which at the same time are safe and non-toxic.


Patent
National University of Ireland | Date: 2017-02-10

An implant (30) for a mammalian bone joint (3) for spacing a first bone (2) of the joint from a second bone (1) of the joint while allowing translational movement of the second bone in relation to the first bone is described. The implant comprises (a) a distal part (31) configured for intramedullary engagement with an end of the second bone, (b) a proximal part (34) having a platform (15) configured for non-engaging abutment of an end of the first bone and translational movement thereon, and (c) an articulating coupling (10, 16) provided between the distal and proximal ends allowing controlled articulation of the first and second bones. The bone-abutting platform is shaped to conform to and translate upon the end of the first bone. A kit for assembly to form the implant of the invention, and the use of the implant to treat osteoarthritis in a bone joint, are also described.


Patent
National University of Ireland | Date: 2017-08-16

An implant (5) for a mammalian bone joint (3) for spacing a first bone (2) of the joint from a second bone (1) of the joint while allowing translational movement of the second bone in relation to the first bone is described. The implant comprises (a) a distal part (6) configured for intramedullaiy engagement with an end of the second bone, (b) a proximal part having a platform (15) configured for non-engaging abutment of an end of the first bone and at least partial translational movement thereon, and (c) an articulating coupling (10, 16) provided between the distal and proximal ends allowing controlled articulation of the first and second bones. The bone-abutting platform is shaped to conform to and translate upon the end of the first bone. A kit for assembly to form the implant of the invention, and the use of the implant to treat osteoarthritis in a bone joint, are also described.


Patent
National University of Ireland | Date: 2015-02-16

A serum-free medium for the growth of mesenchymal stem cells comprises FGF, TGF- and lipoprotein.


Patent
National University of Ireland | Date: 2015-02-12

A population of human stem cells is, or is selected to be, positive for CD271 and acetylated tubulin. Cells are isolated by a method comprising isolation of a cell from a mixed population of cells based on expression of cell surface markers, wherein the markers are CD271 and acetylated tubulin. The isolated cells may be used in therapy for example by producing tissues such as bone, cartilage or tendon, or in pharmaceutical compositions comprising isolated cells.


Patent
National University of Ireland | Date: 2017-09-13

A thrombectomy device for removing thrombus from a body lumen comprises an elongated catheter member (2) having a distal part and a proximal part, a thrombus blocking body (5) disposed on the distal part of the catheter member and radially expansible between a contracted orientation and an expanded, thrombus-blocking, orientation, a thrombus capture body (3) disposed on the distal part of the catheter member in an axially spaced-apart relationship to the thrombus blocking body, and radially expansible between a contracted orientation and an expanded, thrombus-capture, orientation, deployment means actuable to deploy and retract the thrombus capture body and thrombus blocking body; and an elongated control arm operably connected to the thrombus capture body. The thrombus capture body is a cage having an inwardly tapering leading end, the elongated control arm is operably connected to the leading end of the cage, and a thrombus extractor or macerator mechanism is disposed within the cage.


Grant
Agency: European Commission | Branch: H2020 | Program: IA | Phase: ICT-15-2016-2017 | Award Amount: 18.70M | Year: 2017

Big Data will have a profound economic and societal impact in the mobility and logistics sector, which is one of the most-used industries in the world contributing to approximately 15% of GDP. Big Data is expected to lead to 500 billion USD in value worldwide in the form of time and fuel savings, and savings of 380 megatons CO2 in mobility and logistics. With freight transport activities projected to increase by 40% in 2030, transforming the current mobility and logistics processes to become significantly more efficient, will have a profound impact. A 10% efficiency improvement may lead to EU cost savings of 100 BEUR. Despite these promises, interestingly only 19 % of EU mobility and logistics companies employ Big Data solutions as part of value creation and business processes. The TransformingTransport project will demonstrate, in a realistic, measurable, and replicable way the transformations that Big Data will bring to the mobility and logistics market. To this end, TransformingTransport, validates the technical and economic viability of Big Data to reshape transport processes and services to significantly increase operational efficiency, deliver improved customer experience, and foster new business models. TransformingTransport will address seven pilot domains of major importance for the mobility and logistics sector in Europe: (1) Smart High-ways, (2) Sustainable Vehicle Fleets, (3) Proactive Rail Infrastructures, (4) Ports as Intelligent Logistics Hubs, (5) Efficient Air Transport, (6) Multi-modal Urban Mobility, (7) Dynamic Supply Chains. The TransformingTransport consortium combines knowledge and solutions of major European ICT and Big Data technology providers together with the competence and experience of key European industry players in the mobility and logistics domain.


Grant
Agency: European Commission | Branch: H2020 | Program: IA | Phase: IoT-01-2016 | Award Amount: 25.77M | Year: 2017

ACTIVAGE is a European Multi Centric Large Scale Pilot on Smart Living Environments. The main objective is to build the first European IoT ecosystem across 9 Deployment Sites (DS) in seven European countries, reusing and scaling up underlying open and proprietary IoT platforms, technologies and standards, and integrating new interfaces needed to provide interoperability across these heterogeneous platforms, that will enable the deployment and operation at large scale of Active & Healthy Ageing IoT based solutions and services, supporting and extending the independent living of older adults in their living environments, and responding to real needs of caregivers, service providers and public authorities. The project will deliver the ACTIVAGE IoT Ecosystem Suite (AIOTES), a set of Techniques, Tools and Methodologies for interoperability at different layers between heterogeneous IoT Platforms and an Open Framework for providing Semantic Interoperability of IoT Platforms for AHA, addressing trustworthiness, privacy, data protection and security. User-demand driven interoperable IoT-enabled Active & Healthy Ageing solutions will be deployed on top of the AIOTES in every DS, enhancing and scaling up existing services, for the promotion of independent living, the mitigation of frailty, and preservation of quality of life and autonomy. ACTIVAGE will assess the socio-economic impact, the benefits of IoT-based smart living environments in the quality of life and autonomy, and in the sustainability of the health and social care systems, demonstrating the seamless capacity of integration and interoperability of the IoT ecosystem, and validating new business, financial and organizational models for care delivery, ensuring the sustainability after the project end, and disseminating these results to a worldwide audience. The consortium comprises industries, research centres, SMEs, service providers, public authorities encompassing the whole value chain in every Deployment Site.

Loading National University of Ireland collaborators
Loading National University of Ireland collaborators